PeptidePicker
Home/Peptides/Melanotan I
ClinicalFDA Approved

Melanotan I

Also known as: Afamelanotide · Scenesse · NDP-MSH

An FDA/EMA-approved synthetic alpha-MSH analog that stimulates protective skin pigmentation. Used clinically for Erythropoietic Protoporphyria (EPP).

Dr. Sarah Mitchell

Reviewed by Dr. Sarah Mitchell, PharmD, BCPS

Lead Researcher · 12+ years in peptide therapeutics

Half-Life

~30 minutes

Typical Dose

1 mg (implant) every 2 months

Administration

Subcutaneous implant

Mechanism of Action

Selectively activates MC1R to stimulate eumelanin production, providing deep photoprotective pigmentation without requiring UV exposure.

Key Research Areas

tanningmelanocortinFDA approvedphotoprotection

Frequently Asked Questions

What is Melanotan I?
An FDA/EMA-approved synthetic alpha-MSH analog that stimulates protective skin pigmentation. Used clinically for Erythropoietic Protoporphyria (EPP).
How does Melanotan I work?
Selectively activates MC1R to stimulate eumelanin production, providing deep photoprotective pigmentation without requiring UV exposure.
What is the recommended dosage for Melanotan I?
The typical research dosage is 1 mg (implant) every 2 months, administered via Subcutaneous implant. Dosage protocols vary by study and should be determined by a qualified healthcare professional.
What is the half-life of Melanotan I?
The half-life of Melanotan I is approximately ~30 minutes. This affects dosing frequency and timing in research protocols.
Is Melanotan I FDA approved?
Yes, Melanotan I is FDA approved for specific medical indications. Consult your physician for proper medical guidance.

Research Disclaimer

The information provided about Melanotan I is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.

Related Peptides in Clinical